{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parcha V"],"funding":["NHLBI NIH HHS"],"pagination":["e003353"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8692353"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(6)"],"pubmed_abstract":["<h4>Background</h4>Among patients receiving percutaneous coronary intervention (PCI), the role of a genotype-guided approach for antiplatelet therapy compared with usual care is unclear. We conducted a Bayesian analysis of the entire TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) randomized clinical trial population to evaluate the effect of the genotype-guided antiplatelet therapy post-PCI compared with the usual care on the risk of major adverse cardiovascular events (MACE).<h4>Methods</h4>The primary outcome for our study was the composite of MACE (myocardial infarction, stroke, and cardiovascular death). Secondary outcomes included cardiovascular death, stroke, myocardial infarction, stent "],"journal":["Circulation. Genomic and precision medicine"],"pubmed_title":["Genotype-Guided P2Y<sub>12</sub> Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis."],"pmcid":["PMC8692353"],"funding_grant_id":["U01 HL128606","K23 HL146887"],"pubmed_authors":["Pereira NL","Arora P","Heindl BF","Parcha V","Kalra R","Limdi NA","Li P","Arora G"],"additional_accession":[]},"is_claimable":false,"name":"Genotype-Guided P2Y<sub>12</sub> Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis.","description":"<h4>Background</h4>Among patients receiving percutaneous coronary intervention (PCI), the role of a genotype-guided approach for antiplatelet therapy compared with usual care is unclear. We conducted a Bayesian analysis of the entire TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) randomized clinical trial population to evaluate the effect of the genotype-guided antiplatelet therapy post-PCI compared with the usual care on the risk of major adverse cardiovascular events (MACE).<h4>Methods</h4>The primary outcome for our study was the composite of MACE (myocardial infarction, stroke, and cardiovascular death). Secondary outcomes included cardiovascular death, stroke, myocardial infarction, stent ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-04T19:38:16.308Z","creation":"2025-04-04T19:38:16.308Z"},"accession":"S-EPMC8692353","cross_references":{"pubmed":["34670396"],"doi":["10.1161/CIRCGEN.121.003353","10.1161/circgen.121.003353"]}}